SELLAS Life Sciences Group Inc (NASDAQ: SLS)’s stock price has decreased by 0.00 compared to its previous closing price of 1.29. However, the company has seen a -4.44% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-13 that – Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 –
Is It Worth Investing in SELLAS Life Sciences Group Inc (NASDAQ: SLS) Right Now?
Additionally, the 36-month beta value for SLS is 2.45. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SLS is 70.08M and currently, short sellers hold a 12.29% ratio of that float. The average trading volume of SLS on November 20, 2024 was 577.83K shares.
SLS’s Market Performance
SLS stock saw an increase of -4.44% in the past week, with a monthly gain of 8.40% and a quarterly increase of -1.53%. The volatility ratio for the week is 9.42%, and the volatility levels for the last 30 days are 6.90% for SELLAS Life Sciences Group Inc (SLS). The simple moving average for the last 20 days is 5.74% for SLS stock, with a simple moving average of 5.21% for the last 200 days.
Analysts’ Opinion of SLS
Many brokerage firms have already submitted their reports for SLS stocks, with Cantor Fitzgerald repeating the rating for SLS by listing it as a “Overweight.” The predicted price for SLS in the upcoming period, according to Cantor Fitzgerald is $18 based on the research report published on July 21, 2021 of the previous year 2021.
H.C. Wainwright gave a rating of “Buy” to SLS, setting the target price at $11 in the report published on April 02nd of the previous year.
SLS Trading at 4.64% from the 50-Day Moving Average
After a stumble in the market that brought SLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.00% of loss for the given period.
Volatility was left at 6.90%, however, over the last 30 days, the volatility rate increased by 9.42%, as shares surge +11.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.20% upper at present.
During the last 5 trading sessions, SLS fell by -4.44%, which changed the moving average for the period of 200-days by +113.12% in comparison to the 20-day moving average, which settled at $1.2200. In addition, SELLAS Life Sciences Group Inc saw 21.70% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SLS
The total capital return value is set at -2.06. Equity return is now at value -535.10, with -186.64 for asset returns.
Based on SELLAS Life Sciences Group Inc (SLS), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -57.42.
Currently, EBITDA for the company is 0.53 million with net debt to EBITDA at 1.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.26.
Conclusion
In conclusion, SELLAS Life Sciences Group Inc (SLS) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
